"We're pleased to release IVI's OSVP model for non-small cell lung cancer today so value-assessment stakeholders can review, offer input and collaboratively refine not only this model, but also the underlying methods and approach to assessing relative value of therapies," said Jennifer Bright, IVI's Executive Director.
Incorporating patients' perspectives on value is a core goal of IVI's OSVP models, and IVI partnered with LUNGevity Foundation to ensure input from the patient community throughout development of the new OSVP model for NSCLC.
Specifically, the next OSVP modeling platform will focus on epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC).
The research will help inform the structure and content of OSVP patient simulations and decision models.
"OSVP allows users to tailor an assessment based on what they've determined drives value in their patient population," said Jason Shafrin, Ph.D., IVI's Director of Research.
The first OSVP modeling platform focuses on treatments for moderate to severe rheumatoid arthritis, which requires individualized treatment planning and thus rheumatologists' flexibility to find the right therapy regimen for their patients.
Implementing agency : Ministry Of Defence, Land Equipment, Operational Support Vehicle Programme (Osvp
Operational Support Programmes (OSP) comprises of Operational Support Vehicle Programme (OSVP
), Operational Infrastructure Programme (OIP) and Protected Mobility Vehicle Programme (PMVP) areas.